référence |
RT thoracique |
chimiothérapie |
n |
SM |
survie à 2 ans |
p |
Schaake-Koning, 1992 |
30 Gy/10 x + |
I. - |
108 |
13 % |
|
|
II. CDDP (30 mg/m2/sem) |
98 |
19 % |
||||
III. CDDP (6 mg/m2/j) |
102 |
26 % |
||||
Trovo, 1992 |
45 Gy/15x |
I. - |
88 |
10.3 mo |
|
|
II. CDDP (6 mg/m2/j) |
85 |
10.0 mo |
||||
Blanke, 1993 |
60-65 Gy |
I. - |
111 |
46 sem |
13 % |
|
II. CDDP (70 mg/m2/3 sem) |
104 |
43 sem |
18 % |
|||
Jeremic, 1995 |
64,8 Gy (bifractionné) |
I. - |
61 |
8 mo |
25 % |
|
II. 1x/sem CBDCA (100 mg j1,2) + VP 16 (100 mg j1,2,3) |
52 |
18 mo |
35 % |
0,002 |
||
III. 1x/2sem CBDCA (20 mg j1,2) + VP16 (100 mg j1-5) |
56 |
13 mo |
27 % |
NS |
||
Jeremic, 1996 |
69,6 Gy |
I. - |
65 |
14 mo |
26 % |
|
II. CBDCA (50 mg/j) + VP16 (50 mg/j) |
65 |
21 mo |
43 % |
|||
Bonner, 1998 |
60 Gy |
I. - |
33 |
NS |
||
II. CDDP(30x3)- VP16(100x3) x 2 |
32 |
|||||
Ball, 1999 |
60 Gy 1x/j |
I. - |
53 |
NS |
||
II. CBDCA (70 j1-5) |
54 |
|||||
60 Gy 2x/j |
III - |
46 |
||||
IV. CBDCA (70 j1-5) |
51 |
|||||
Clamon, 1999 |
60 Gy j50 après 2 cycles d’induction par CDDP-VBL |
I. – |
120 |
13 mo |
NS |
|
II. CBDCA 100 mg/m²/ sem |
130 |
13 mo |
||||
Groen, 2004 |
60 Gy (2 Gy/j 5x/sem) |
I. - |
78 |
11,7 mo |
28 % |
NS |
II. CBDCA 20 mg/m²/j |
82 |
11,8 mo |
20 % |
|||
Cakir, 2004 |
64 Gy (2 Gy/j 5x/sem) |
I. - |
88 |
2% (3 ans) |
0,0002 |
|
II. CDDP (20 j1-5) |
88 |
10 % (3 ans) |